[32] Dieci M V, Griguolo G, Bottosso M, et al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy[J]. NPJ Breast Cancer, 2021, 7(1):101. ...
为探究 CCN5 和 ER 在晚期乳腺癌中的作用,研究人员展开研究,发现二者在 DCIS 组织高表达且正相关,意义重大。 在女性健康的领域中,乳腺癌(Breast Cancer,BC)宛如一颗阴霾,笼罩着众多女性的生命健康。它是全球女性中最为常见的恶性肿瘤,其中晚期乳腺癌,也就是乳腺癌发展至最严重阶段的 3 期(局部晚期疾病)和 4 ...
雌激素受体(estrogen receptor,ER)作为乳腺癌的生物学标志物,影响着乳腺癌内分泌治疗的选择。美国临床肿瘤学会和美国病理学家学会(American Society of Clinical Oncology /College of American Pathologists,ASCO/CAP)指南(2010年)将ER≥1%定为ER阳性,ER<1%定为ER阴性。ASCO/CAP指南(2020年)中,新增ER在1%～10%定...
Cancer 74:864-871, 1994.Gotteland M., E. May, F. May-Levin, G. Contesso, J. C. Delarue, and H. Mouriesse. 1994. Estrogen receptors (ER) in human breast cancer: the sig- nificance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer 74:864-871....
2. Howell, S.J., Johnston, S.R., and Howell, A. (2004). The use of selective estro- gen receptor modulators and selective estrogen receptor down-regulators in breast cancer.Best Pract. Res. Clin. Endocrinol. Metab. 18, 47–66.3. Shiau, A.K., Barstad, D., Loria, P.M., Cheng...
Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014;144(1):11-19. doi:10.1007/s10549-014-2847-4.Fuqua SA, Gu G, Rechoum Y (2014) Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer ...
与此同时,美国威斯康星大学 Carbone癌症中心(UWCCC)的Johanna E. Poterala和Kari B. Wisinski同期发表了题为“Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy”...
Goetz, M.; Forero, A.; Hoog, J.; Naughton, M.; Ademuyiwa, F.; Suresh, R.; et al. Neopalana: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin. Cancer Res. 2017, 23, 4055–4065...
2. Howell, S.J., Johnston, S.R., and Howell, A. (2004). The use of selective estro- gen receptor modulators and selective estrogen receptor down-regulators in breast cancer.Best Pract. Res. Clin. Endocrinol. Metab.18, 47–66.
据最新发表于CA Cancer J Clin杂志的全球癌症数据统计,全球每年乳腺癌新发病例约210万,死亡病例62.7万,在所有导致死亡的癌症类型中排名第二【1】。乳腺癌细胞可以依据其表达雌激素受体(Estrogen receptor, ER)、孕激素受体 (Progesterone receptor, PR) 的情况以及表皮生长因子受体2(Epidermal growth factor receptor ...